FDA Grants Viatris Approval for Generic of Astra’s Symbicort

FDA granted Mylan Pharmeceuticals, now Viatris, approval for the first generic of AstraZeneca’s symbicort (budesonide and formoterol fumarate dihydrate) inhalation aerosol for the treatment of asthma in patients six years of age and older and the maintenance treatment of airflow obstruction and reducing exacerbations for patients with chronic obstructive pulmonary disease COPD, including chronic bronchitis and/or emphysema.

• NOTE: Dec. 2021, Viatris Bid to Sell Generic of Astra’s Symbicort Gets New Life

NOTE

• Viatris Inc. rose 1.5% to $9.96 as of 3:51 p.m. New York time
  • 11 holds, 5 buys, 0 sells

To view the source of this information, click here ...